Levosimendan Kabi

Levosimendan, the active ingredient in Levosimendan Kabi, is a calcium sensitizer / inodilator presented as an injectable solution for intravenous infusion use. It treats acute decompensated heart failure in adult patients. GNH USA supplies Levosimendan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan acts on the cardiovascular system to improve cardiac performance in heart‑failure states. - Acute decompensated heart failure: enhances cardiac output and relieves symptoms of congestion. - Cardiogenic shock (off‑label): provides hemodynamic support when conventional therapy is insufficient. - Heart failure with reduced ejection fraction: improves contractility and reduces afterload, aiding functional recovery.

Levosimendan may cause a range of adverse reactions during and after infusion.

Common Side Effects: - Hypotension: drop in blood pressure, especially during rapid infusion. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate. - Atrial fibrillation: new‑onset irregular rhythm.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion. - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Anaphylactic reaction: rare hypersensitivity requiring immediate intervention. - Hepatic dysfunction: elevated liver enzymes in susceptible patients.

Levosimendan requires careful monitoring and patient selection to minimise risks. - Cardiovascular monitoring: continuously observe blood pressure and heart rate during infusion. - Renal impairment: adjust infusion rate and monitor renal function closely. - Electrolyte disturbances: correct hypokalemia or hypomagnesemia before administration. - Concomitant vasodilators: use with caution due to additive hypotensive effect. - Beta‑blockers and calcium channel blockers: may blunt therapeutic response; monitor closely. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Sodium nitroprusside: additive vasodilation may cause severe hypotension. - Beta‑blockers: may reduce inotropic effect of levosimendan. - Calcium channel blockers: increase risk of arrhythmias.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotension; monitor volume status. - ACE inhibitors/ARBs: combined effect on blood pressure requires observation. - Other inotropes (dobutamine, milrinone): overlapping mechanisms may necessitate dose adjustment.